Redwood Pharma AB (publ) to conduct rights issue

Subscription period 1 June – 20 June 2017

(Units comprising one equity share and one option)


Redwood Pharma AB is a company whose mission is to develop new ophthalmic pharmaceutical therapies where there are large and unmet market needs. It has in-licensed, IntelliGel, a proprietary and patented hydrogel drug delivery platform technology that will reduce dosages, dosing-frequency and, thereby, potential systemic toxicities of active pharmaceutical ingredients. The Company’s lead development product is a new therapy to treat chronic Dry Eye Disease (DED) in post-menopausal women. With an ageing population, DED affects more and more people hindering many in their daily activities such as reading, using a computer and driving an automobile.

Latest Events

22 March, 2017 – Analyst Group presents investment analysis of Redwood Pharma
February 15, 2017 – Redwood Pharma AB presenting End of Year Report 2016
November 24, 2016 – Redwood Pharma AB presenting Interim Report Q3 2016
November 19, 2016 – Redwood Pharma AB to present at Aktiespararna conference in Örebro
August 30, 2016 – Redwood Pharma AB presenting Interim Report January – June 2016